CYP2J3 Gene Delivery Reduces Insulin Resistance via Upregulation of eNOS in Fructose-treated Rats

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Xu, Xizhen ^a   Tu, Ling ^a   Wang, Luyun ^b   Fang, Xiaosai ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOCHROME P450; CYTOCHROME P450 2J3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPOXYICOSATRIENOIC ACID; FRUCTOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N(G) METHYLARGININE; PHOSPHATIDYLINOSITOL 3 KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CYP2J3 PROTEIN, RAT; NOS3 PROTEIN, RAT; RECOMBINANT PROTEIN; UNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE TARGETING; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINE OSMOLALITY; ANIMAL; BLOOD PRESSURE; GENE TRANSFER; GENETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS, UNSATURATED; FRUCTOSE; GENE TRANSFER TECHNIQUES; INSULIN RESISTANCE; MALE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION; VASODILATION;

EID: 83755228848     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-114     Document Type: Article

References (23)

1. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch 2010, 459(6):793-806. 10.1007/s00424-009-0767-7, 20012875.
2. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001, 108(9):1341-1348. 209429, 11696579.
3. Miatello R, Risler N, Castro C, Gonzalez S, Ruttler M, Cruzado M. Aortic smooth muscle cell proliferation and endothelial nitric oxide synthase activity in fructose-fed rats. Am J Hypertens 2001, 14(11 Pt 1):1135-1141.
4. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000, 20(2):545-550. 10.1161/01.ATV.20.2.545, 10669655.
5. Zhao CX, Xu X, Cui Y, Wang P, Wei X, Yang S, Edin ML, Zeldin DC, Wang DW. Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J Pharmacol Exp Ther 2009, 328(2):610-620. 10.1124/jpet.108.143396, 2682272,2682272, 19008412.
6. Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011,
7. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 2003, 307(2):753-764. 10.1124/jpet.103.052787, 12975498.
8. Jiang JG, Chen RJ, Xiao B, Yang S, Wang JN, Wang Y, Cowart LA, Xiao X, Wang DW, Xia Y. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 2007, 82(1-4):162-174. 10.1016/j.prostaglandins.2006.08.005, 17164144.
9. Xu X, Zhao CX, Wang L, Tu L, Fang X, Zheng C, Edin ML, Zeldin DC, Wang DW. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 2010, 59(4):997-1005. 10.2337/db09-1241, 2844847, 20068141.
10. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, Da CGA, Huang Y, Luft FC, Gollasch M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29(1):54-60. 10.1161/ATVBAHA.108.171298, 18927469.
11. Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW, Zeldin DC. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 2003, 42(5):1026-1033. 10.1161/01.HYP.0000097603.55404.35, 14568997.
12. Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X, Voltz JW, Zeldin DC, Wang DW. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010, 334(3):784-794. 10.1124/jpet.110.167510, 2939659, 20501636.
13. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. Faseb J 2010, 24(10):3770-3781. 10.1096/fj.10-160119, 2996903, 20495177.
14. Jiang H, Quilley J, Doumad AB, Zhu AG, Falck JR, Hammock BD, Stier CJ, Carroll MA. Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2011, 300(6):H1990-H1996. 10.1152/ajpheart.01267.2010, 21398593.
15. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, et al. Increased blood pressure in mice lacking cytochrome P450 2J5. Faseb J 2008, 22(12):4096-4108. 10.1096/fj.08-114413, 2614614, 18716027.
16. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, Da CGA, Huang Y, Luft FC, Gollasch M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29(1):54-60. 10.1161/ATVBAHA.108.171298, 18927469.
17. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105(14):1656-1662. 10.1161/01.CIR.0000012748.58444.08, 11940543.
18. Elrod JW, Duranski MR, Langston W, Greer JJ, Tao L, Dugas TR, Kevil CG, Champion HC, Lefer DJ. eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ Res 2006, 99(1):78-85. 10.1161/01.RES.0000231306.03510.77, 16763164.
19. Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, Hung CH, Shin SJ, Chen HJ, Lee YJ. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 2010, 118(6):346-352. 10.1055/s-0029-1243604, 20140850.
20. Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S, Daum G, Handa P, Schwartz MW, Kim F. Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol 2010, 30(4):758-765. 10.1161/ATVBAHA.109.199893, 2865555, 20093624.
21. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2009, 284(3):1803-1812.
22. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006, 3(6):403-416. 10.1016/j.cmet.2006.05.005, 16753576.
23. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M, Tomaszewska R, Cooke JP, Dembinska-Kiec A. Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance. Cardiovasc Diabetol 2011, 10:68. 10.1186/1475-2840-10-68, 3212914, 21781316.